Search research articles
Contact Us
Filters
Showing results (101-110 of 117) with videos related to
Page
of 12
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
January 9, 2026
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Liver Cancer
|
June 3, 2026
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
April 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Fujimasa Tada, Atsushi Hiraoka, Hideko Ohama, et al.
Hepatology (Baltimore, Md.)
|
May 6, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
Kaho Aoe, Toshifumi Tada, Atsushi Hiraoka, et al.
Journal of Cancer Research and Clinical Oncology
|
March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
Targeted Oncology
|
March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
International Journal of Cancer
|
November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
Oncology
|
January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 117) with videos related to
Sort By:
Page
of 12
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
January 9, 2026
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Liver Cancer
|
June 3, 2026
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
April 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Fujimasa Tada, Atsushi Hiraoka, Hideko Ohama, et al.
Hepatology (Baltimore, Md.)
|
May 6, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
Kaho Aoe, Toshifumi Tada, Atsushi Hiraoka, et al.
Journal of Cancer Research and Clinical Oncology
|
March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
Targeted Oncology
|
March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
International Journal of Cancer
|
November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
Oncology
|
January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
Page
of 12